J Korean Assoc Oral Maxillofac Surg.  2020 Oct;46(5):335-340. 10.5125/jkaoms.2020.46.5.335.

Efficacy of botulinum toxin in the management of temporomandibular myofascial pain and sleep bruxism

• Hosgor H
• Altindis S

• KMID: 2508258
• DOI: http://doi.org/10.5125/jkaoms.2020.46.5.335

Abstract

Objectives
This study sought to evaluate the efficacy of injecting botulinum toxin into the masseter and temporal muscles in patients with temporomandibular myofascial pain and sleep bruxism.
Materials and Methods
The study was conducted based on a clinical record review of 44 patients (36 females and eight males; mean age, 35.70±12.66 years). Patients who underwent the injection of botulinum toxin into the masseter and temporal muscles for the management of temporomandibular myofascial pain and sleep bruxism were included in the study. Patients were diagnosed based on the Diagnostic Criteria for Temporomandibular Disorders. Sleep bruxism was diagnosed according to the criteria defined by the American Academy of Sleep Medicine. The values of the visual analogue scale (VAS) and range of jaw motion, including unassisted maximum mouth opening (MMO), protrusion, and right and left laterotrusion, were observed preoperatively and postoperatively at one-, three-, and six-month follow-up visits.
Results
MMO, movements of the right and the left laterotrusion, and protrusion increased significantly (P<0.05), while VAS ratings decreased significantly at the three follow-up points relative to baseline values (P<0.05).
Conclusion
Botulinum toxin is an effective treatment for patients with temporomandibular myofascial pain and sleep bruxism.

Keyword

Temporomandibular joint disorders; Sleep bruxism; Botulinum toxin

Figure

• 

  Fig. 1 The distribution of maximum mouth opening (MMO), right laterotrusion, left laterotrusion, protrusion, and visual analogue scale (VAS) scores at baseline, 1st-month, 3rd-month, and 6th-month.

Reference

References

1. Lora VR, Canales Gde L, Gonçalves LM, Meloto CB, Barbosa CM. 2016; Prevalence of temporomandibular disorders in postmenopausal women and relationship with pain and HRT. Braz Oral Res. 30:e100. https://doi.org/10.1590/1807-3107BOR-2016.vol30.0100 . DOI: 10.1590/1807-3107BOR-2016.vol30.0100. PMID: 27556676.

2. Nayyar P, Kumar P, Nayyar PV, Singh A. 2014; Botox: broadening the horizon of dentistry. J Clin Diagn Res. 8:ZE25–9. https://doi.org/10.7860/JCDR/2014/11624.5341 . DOI: 10.7860/JCDR/2014/11624.5341. PMID: 25654058. PMCID: PMC4316364.

3. Miloro M, Ghali GE, Larsen P, Waite P. 2012. Peterson's principles of oral and maxillofacial surgery. 3rd ed. People's Medical Publishing House;Shelton:

4. Maini K, Dua A. 2020. Temporomandibular joint syndrome [Internet]. StatPearls Publishing;Treasure Island (FL): Available from: https://www.ncbi.nlm.nih.gov/books/NBK551612/ . cited 2020 May 10.

5. Koyano K, Tsukiyama Y, Ichiki R, Kuwata T. 2008; Assessment of bruxism in the clinic. J Oral Rehabil. 35:495–508. https://doi.org/10.1111/j.1365-2842.2008.01880.x . DOI: 10.1111/j.1365-2842.2008.01880.x. PMID: 18557916.

6. Jiménez-Silva A, Peña-Durán C, Tobar-Reyes J, Frugone-Zambra R. 2017; Sleep and awake bruxism in adults and its relationship with temporomandibular disorders: a systematic review from 2003 to 2014. Acta Odontol Scand. 75:36–58. https://doi.org/10.1080/00016357.2016.1247465 . DOI: 10.1080/00016357.2016.1247465. PMID: 27796166.

7. Macfarlane TV, Gray RJM, Kincey J, Worthington HV. 2001; Factors associated with the temporomandibular disorder, pain dysfunction syndrome (PDS): Manchester case-control study. Oral Dis. 7:321–30. https://doi.org/10.1034/j.1601-0825.2001.00758.x . DOI: 10.1034/j.1601-0825.2001.00758.x. PMID: 11834094.

8. Glaros AG, Burton E. 2004; Parafunctional clenching, pain, and effort in temporomandibular disorders. J Behav Med. 27:91–100. https://doi.org/10.1023/b:jobm.0000013646.04624.8f . DOI: 10.1023/B:JOBM.0000013646.04624.8f. PMID: 15065478.

9. van der Meulen MJ, Lobbezoo F, Aartman IH, Naeije M. 2006; Self-reported oral parafunctions and pain intensity in temporomandibular disorder patients. J Orofac Pain. 20:31–5. PMID: 16483018.

10. Magnusson T, Egermarki I, Carlsson GE. 2005; A prospective investigation over two decades on signs and symptoms of temporomandibular disorders and associated variables. A final summary. Acta Odontol Scand. 63:99–109. https://doi.org/10.1080/00016350510019739 . DOI: 10.1080/00016350510019739. PMID: 16134549.

11. Ciancaglini R, Gherlone EF, Radaelli G. 2001; The relationship of bruxism with craniofacial pain and symptoms from the masticatory system in the adult population. J Oral Rehabil. 28:842–8. https://doi.org/10.1046/j.1365-2842.2001.00753.x . DOI: 10.1046/j.1365-2842.2001.00753.x. PMID: 11580822.

12. Uchida M, Yatani H, Ishigaki S, Toda M, Morimoto K. 2008; Relations among TMD, bruxism, lifestyle, and psychological stress. Prosthodont Res Pract. 7:171–3. DOI: 10.2186/prp.7.171.

13. Lobbezoo F, Ahlberg J, Raphael KG, Wetselaar P, Glaros AG, Kato T, et al. 2018; International consensus on the assessment of bruxism: report of a work in progress. J Oral Rehabil. 45:837–44. https://doi.org/10.1111/joor.12663 . DOI: 10.1111/joor.12663. PMID: 29926505. PMCID: PMC6287494.

14. Manfredini D, Winocur E, Guarda-Nardini L, Paesani D, Lobbezoo F. 2013; Epidemiology of bruxism in adults: a systematic review of the literature. J Orofac Pain. 27:99–110. https://doi.org/10.11607/jop.921 . DOI: 10.11607/jop.921. PMID: 23630682.

15. Maluly M, Andersen ML, Dal-Fabbro C, Garbuio S, Bittencourt L, de Siqueira JT, et al. 2013; Polysomnographic study of the prevalence of sleep bruxism in a population sample. J Dent Res. 92(7 Suppl):97S–103S. DOI: 10.1177/0022034513484328. PMID: 23690359.

16. Ohayon MM, Li KK, Guilleminault C. 2001; Risk factors for sleep bruxism in the general population. Chest. 119:53–61. https://doi.org/10.1378/chest.119.1.53 . DOI: 10.1378/chest.119.1.53. PMID: 11157584.

17. American Academy of Sleep Medicine. 2014. International classification of sleep disorders. 3rd ed. American Academy of Sleep Medicine;Darien (IL): p. 303–11.

18. Suvinen TI, Reade PC, Hanes KR, Könönen M, Kemppainen P. 2005; Temporomandibular disorder subtypes according to self-reported physical and psychosocial variables in female patients: a re-evaluation. J Oral Rehabil. 32:166–73. https://doi.org/10.1111/j.1365-2842.2004.01432.x . DOI: 10.1111/j.1365-2842.2004.01432.x. PMID: 15707426.

19. List T, Axelsson S. 2010; Management of TMD: evidence from systematic reviews and meta-analyses. J Oral Rehabil. 37:430–51. https://doi.org/10.1111/j.1365-2842.2010.02089.x . DOI: 10.1111/j.1365-2842.2010.02089.x. PMID: 20438615.

20. Freund B, Schwartz M, Symington JM. 1999; The use of botulinum toxin for the treatment of temporomandibular disorders: preliminary findings. J Oral Maxillofac Surg. 57:916–20. discussion920-1. https://doi.org/10.1016/s0278-2391(99)90007-1 . DOI: 10.1016/S0278-2391(99)90007-1. PMID: 10437718.

21. Lee KM, Chow J, Hui E, Li W. 2005; Botulinum toxin type A injection for the management of myofascial temporomandibular pain disorder. Asian J Oral Maxillofac Surg. 17:100–3. https://doi.org/10.1016/S0915-6992(05)80032-9 . DOI: 10.1016/S0915-6992(05)80032-9.

22. De la Torre Canales G, Câmara-Souza MB, do Amaral CF, Garcia RC, Manfredini D. 2017; Is there enough evidence to use botulinum toxin injections for bruxism management? A systematic literature review. Clin Oral Investig. 21:727–34. https://doi.org/10.1007/s00784-017-2092-4 . DOI: 10.1007/s00784-017-2092-4. PMID: 28255752.

23. Schiffman E, Ohrbach R, Truelove E, Look J, Anderson G, Goulet JP, et al. 2014; ; International RDC/TMD Consortium Network, International association for Dental Research; Orofacial Pain Special Interest Group, International Association for the Study of Pain. Diagnostic criteria for temporomandibular disorders (DC/TMD) for clinical and research applications: recommendations of the International RDC/TMD Consortium Network* and Orofacial Pain Special Interest Group†. J Oral Facial Pain Headache. 28:6–27. https://doi.org/10.11607/jop.1151 . DOI: 10.11607/jop.1151. PMID: 24482784. PMCID: PMC4478082.

24. Nitzan DW. 1994; Intraarticular pressure in the functioning human temporomandibular joint and its alteration by uniform elevation of the occlusal plane. J Oral Maxillofac Surg. 52:671–9. discussion 679–80. https://doi.org/10.1016/0278-2391(94)90476-6 . DOI: 10.1016/0278-2391(94)90476-6. PMID: 8006730.

25. Sharav Y, Benoliel R. 2008. Orofacial pain & headache. Mosby;Edinburgh: p. 161. DOI: 10.1016/B978-0-7234-3412-2.10005-7.

26. Güleç M, Taşsöker M, Özcan S. 2019; [Bruksizmin tanı ve tedavisinde güncel yaklaşımlar]. Selcuk Dent J. 6:221–8. Turkish.

27. Tinastepe N, Küçük BB, Oral K. 2015; Botulinum toxin for the treatment of bruxism. Cranio. 33:291–8. https://doi.org/10.1080/08869634.2015.1097296 . DOI: 10.1080/08869634.2015.1097296. PMID: 26715152.

28. Manfredini D, Lobbezoo F. 2010; Relationship between bruxism and temporomandibular disorders: a systematic review of literature from 1998 to 2008. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 109:e26–50. https://doi.org/10.1016/j.tripleo.2010.02.013 . DOI: 10.1016/j.tripleo.2010.02.013. PMID: 20451831.

29. Ariji Y, Sakuma S, Izumi M, Sasaki J, Kurita K, Ogi N, et al. 2004; Ultrasonographic features of the masseter muscle in female patients with temporomandibular disorder associated with myofascial pain. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 98:337–41. https://doi.org/10.1016/j.tripleo.2004.06.068 . DOI: 10.1016/j.tripleo.2004.06.068. PMID: 15356473.

30. Abouelhuda AM, Khalifa AK, Kim YK, Hegazy SA. 2018; Non-invasive different modalities of treatment for temporomandibular disorders: review of literature. J Korean Assoc Oral Maxillofac Surg. 44:43–51. https://doi.org/10.5125/jkaoms.2018.44.2.43 . DOI: 10.5125/jkaoms.2018.44.2.43. PMID: 29732308. PMCID: PMC5932270.

31. Fernández-Núñez T, Amghar-Maach S, Gay-Escoda C. 2019; Efficacy of botulinum toxin in the treatment of bruxism: systematic review. Med Oral Patol Oral Cir Bucal. 24:e416–24. https://doi.org/10.4317/medoral.22923 . DOI: 10.4317/medoral.22923. PMID: 31246937. PMCID: PMC6667018.

32. Al-Wayli H. 2017; Treatment of chronic pain associated with nocturnal bruxism with botulinum toxin. A prospective and randomized clinical study. J Clin Exp Dent. 9:e112–7. https://doi.org/10.4317/jced.53084 . DOI: 10.4317/jced.53084. PMID: 28149474. PMCID: PMC5268105.

33. Sidebottom AJ, Patel AA, Amin J. 2013; Botulinum injection for the management of myofascial pain in the masticatory muscles. A prospective outcome study. Br J Oral Maxillofac Surg. 51:199–205. https://doi.org/10.1016/j.bjoms.2012.07.002 . DOI: 10.1016/j.bjoms.2012.07.002. PMID: 22871559.

34. Ahn J, Horn C, Blitzer A. 2004; Botulinum toxin for masseter reduction in Asian patients. Arch Facial Plast Surg. 6:188–91. https://doi.org/10.1001/archfaci.6.3.188 . DOI: 10.1001/archfaci.6.3.188. PMID: 15148129.

35. Majid OW. 2010; Clinical use of botulinum toxins in oral and maxillofacial surgery. Int J Oral Maxillofac Surg. 39:197–207. https://doi.org/10.1016/j.ijom.2009.10.022 . DOI: 10.1016/j.ijom.2009.10.022. PMID: 19959337.

36. Dressler D, Saberi FA, Barbosa ER. 2005; Botulinum toxin: mechanisms of action. Arq Neuropsiquiatr. 63:180–5. https://doi.org/10.1590/s0004-282x2005000100035 . DOI: 10.1590/S0004-282X2005000100035. PMID: 15830090.

37. Lee SJ, McCall WD Jr, Kim YK, Chung SC, Chung JW. 2010; Effect of botulinum toxin injection on nocturnal bruxism: a randomized controlled trial. Am J Phys Med Rehabil. 89:16–23. https://doi.org/10.1097/PHM.0b013e3181bc0c78 . DOI: 10.1097/PHM.0b013e3181bc0c78. PMID: 19855255.

38. Guarda-Nardini L, Manfredini D, Salamone M, Salmaso L, Tonello S, Ferronato G. 2008; Efficacy of botulinum toxin in treating myofascial pain in bruxers: a controlled placebo pilot study. Cranio. 26:126–35. https://doi.org/10.1179/crn.2008.017 . DOI: 10.1179/crn.2008.017. PMID: 18468272.

39. Guarda-Nardini L, Stecco A, Stecco C, Masiero S, Manfredini D. 2012; Myofascial pain of the jaw muscles: comparison of short-term effectiveness of botulinum toxin injections and fascial manipulation technique. Cranio. 30:95–102. https://doi.org/10.1179/crn.2012.014 . DOI: 10.1179/crn.2012.014. PMID: 22606852.

40. Ernberg M, Hedenberg-Magnusson B, List T, Svensson P. 2011; Efficacy of botulinum toxin type A for treatment of persistent myofascial TMD pain: a randomized, controlled, double-blind multicenter study. Pain. 152:1988–96. https://doi.org/10.1016/j.pain.2011.03.036 . DOI: 10.1016/j.pain.2011.03.036. PMID: 21514731.

41. Kim HS, Yun PY, Kim YK. 2016; A clinical evaluation of botulinum toxin-A injections in the temporomandibular disorder treatment. Maxillofac Plast Reconstr Surg. 38:5. https://doi.org/10.1186/s40902-016-0051-7 . DOI: 10.1186/s40902-016-0051-7. PMID: 26855937. PMCID: PMC4729782.

42. Kurtoglu C, Gur OH, Kurkcu M, Sertdemir Y, Guler-Uysal F, Uysal H. 2008; Effect of botulinum toxin-A in myofascial pain patients with or without functional disc displacement. J Oral Maxillofac Surg. 66:1644–51. https://doi.org/10.1016/j.joms.2008.03.008 . DOI: 10.1016/j.joms.2008.03.008. PMID: 18634953.

43. Klein FH, Brenner FM, Sato MS, Robert FM, Helmer KA. 2014; Lower facial remodeling with botulinum toxin type A for the treatment of masseter hypertrophy. An Bras Dermatol. 89:878–84. https://doi.org/10.1590/abd1806-4841.20143200 . DOI: 10.1590/abd1806-4841.20143200. PMID: 25387491. PMCID: PMC4230655.

44. Borodic G. 2007; Botulinum toxin, immunologic considerations with long-term repeated use, with emphasis on cosmetic applications. Facial Plast Surg Clin North Am. 15:11–6. v https://doi.org/10.1016/j.fsc.2006.10.001 . DOI: 10.1016/j.fsc.2006.10.001. PMID: 17317551.

45. Chen YW, Chiu YW, Chen CY, Chuang SK. 2015; Botulinum toxin therapy for temporomandibular joint disorders: a systematic review of randomized controlled trials. Int J Oral Maxillofac Surg. 44:1018–26. https://doi.org/10.1016/j.ijom.2015.04.003 . DOI: 10.1016/j.ijom.2015.04.003. PMID: 25920597.